Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Published: Aug. 5, 2010, 9:29 p.m.

b"

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.

"